BioSpace News Archive

Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that members of the Aruvant leadership team will participate in the annual Cell & Gene Meeting on the Mesa which is taking place in person in Carlsbad, CA and online from October 12 to October 14, 2021

TriSalus Life Sciences®, an interventional immunotherapy company on a mission to improve the lives of patients living with liver and pancreatic cancers by dramatically transforming the way these devastating diseases are treated, announced the appointment of Sean Murphy to its Board of Directors.

iotaMotion Inc., a leader in developing advanced surgical systems for cochlear implant surgery, announced FDA granted its’ De Novo classification request to market the iotaSOFT™ insertion system.

Transaction concludes with the launch of “Awakn Clinics Oslo AS” as part of Awakn Life Sciences Nordic Expansion.

William A. Hartman, Halberd’s Chairman, President & CEO, stated, “We are pleased that our product will now also be available through Amazon, and will be able to reach virtually anyone in need of immunity support to maintain their body’s health and resistance to diseases.

Halomine™ Inc., a pioneer in advanced technology for managing surfaces and providing long term protection against viruses, bacteria, and fungi, today announced that it has received a National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase II grant for $1M to advance their flagship product that can provide residual antimicrobial protection against a wide variety of dangerous pathogens.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology and IVUS solutions, today announced that a worldwide committee of 40 cross-specialty medical experts achieved the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease (PVD) interventions.

Pulmodyne, Inc., a leading provider of drug atomization delivery, and Alcove Manufacturing and Distribution, Inc., today announced the partnership between the two companies to expand distribution, integrate manufacturing, and to continue joint development of new atomization technologies.

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the first round of 16 highly anticipated late-breaking clinical trial results at VIVA121 hosted at Wynn Las Vegas.

IntelGenx Technologies Corp. announces that it has received final approval to graduate to the Toronto Stock Exchange from the TSX Venture Exchange.